Dow 30 Earnings: Pfizer Fourth Quarter 2016

… quarter of 2015 had a negative impact of roughly $750 million. On the operating front, the company’s Innovative Health segment, which sells newer, patent-protected drugs, contributed sales of $7.7 billion (+1%), driven by continued growth of …

How Big Is the Opportunity for Celgene’s Otezla Overseas?

Since winning approval for use in psoriasis in September 2014, Otezla has steadily been chipping away at U.S. market share in the indication, turning into a billion-dollar blockbuster in the process. Otezla’s sales continued climbing throughout 2016, and with launches planned in new international markets soon, sales could head even higher.

Biosimilars in Europe: 2016 Year in Review and What’s Ahead

Europe’s biosimilar market continues to develop, with biosimilars in new classes approved and pending in applications before the European Medicines Agency . 22 biosimilars are approved in eight different product classes and 16 biosimilar applications, including applications in four new product classes, are pending as of December 1, 2016.

We’re Bullish on Wide-Moat Amgen

Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, and free cash flow as a percentage of sales hovers near 40% as the company undertakes massive cost-cutting and improves manufacturing. Strong newer blockbusters like Prolia/Xgeva and future blockbuster Repatha should defend Amgen’s wide economic moat from erosion caused by biosimilar and branded competition.